MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer

• DOI: 10.1038/srep07546
• Publication Date: 2014-12-18T10:04:03Z
• Authors: Yongbao Wei; Jinrui Yang; Lu Yi; Yinhuai Wang; Zhitao Dong; Ziting Liu; Shifeng Ou-yang; Hongtao Wu; Zhaohui Zhong; Zhuo Yin; Keqin Zhou; Yunliang Gao; Bin Yan; Zhao Wang
• Keywords: Gene Expression Regulation, Neoplastic; Male; 0301 basic medicine; MicroRNAs; 03 medical and health sciences; Cell Line, Tumor; Humans; Prostatic Neoplasms; Article; Septins; Up-Regulation; 3. Good health

MicroRNAs (miRNAs) present frequently altered expression in urologic cancers including prostate, bladder, and kidney cancer. The altered expression of miR-223 has been reported in cancers and other diseases in recent researches. MiR-223 is up-regulated in systemic lupus erythematosus and rheumatoid arthritis. In neoplastic diseases, miR-223 is proved to be up-expressed in plasma or serum and cancer tissues compared with normal tissues in pancreatic cancer, gastric cancer, et al. However, whether altered expression of miR-223 is associated with prostate cancer (PCa) and what it is potential functions in PCa remained unveiled. In this study, we firstly found miR-223-3p were up-regulated in prostate cancer tissues and then we study functional role of miR-223-3p in PCa using DU145, PC3 and LNCaP cell lines. Our data suggested that miR-223-3p might target gene SEPT6 and promoted the biological behavior of prostate cancer. Notably, we found increasing SEPT6 expression might reverse the biological activity induced by miR-223-3p, which might be a potential therapeutic target for PCa.